What plasma short-chain fatty acids are predictors of response to GvHD therapy?

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the GvHD Hub spoke to Shernan G. Holtan, University of Minnesota, Minneapolis, US. We asked, What plasma short-chain fatty acids are predictors of response to graft-versus-host disease therapy?

Holtan describes the results of a clinical trial evaluating how acute GvHD treatment response relates to plasma levels of short-chain fatty acids. In general, levels of butyrate are higher in patients responding to therapy.